Literature DB >> 11427594

Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico.

J Torres1, M Camorlinga-Ponce, G Pérez-Pérez, A Madrazo-De la Garza, M Dehesa, G González-Valencia, O Muñoz.   

Abstract

The susceptibilities to three antimicrobials of 195 Helicobacter pylori strains isolated from Mexican patients is reported; 80% of the strains were resistant to metronidazole, 24% were resistant to clarithromycin, and 18% presented a transient resistance to amoxicillin. Resistance to two or more antimicrobials increased significantly from 1995 to 1997.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11427594      PMCID： PMC88210          DOI： 10.1128/JCM.39.7.2677-2680.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

Review 1.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Furazolidone combination therapies for Helicobacter pylori infection in the United States.

Authors:  D Y Graham; M S Osato; J Hoffman; A R Opekun; S Y Anderson; H M El-Zimaity
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

Review 3.  Review article: nitroimidazole resistance in Helicobacter pylori.

Authors:  E J Van Der Wouden; J C Thijs; A A Van Zwet; J H Kleibeuker
Journal:  Aliment Pharmacol Ther       Date:  2000-01       Impact factor: 8.171

4.  Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents.

Authors:  R Piccolomini; G Di Bonaventura; G Catamo; F Carbone; M Neri
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children.

Authors:  N Kalach; M Bergeret; P H Benhamou; C Dupont; J Raymond
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

6.  Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil.

Authors:  S Mendonça; C Ecclissato; M S Sartori; A P Godoy; R A Guerzoni; M Degger; J Pedrazzoli
Journal:  Helicobacter       Date:  2000-06       Impact factor: 5.753

7.  Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori.

Authors:  C R DeLoney; N L Schiller
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands.

Authors:  E J van der Wouden; A A van Zwet; G D Vosmaer; J A Oom; A de Jong; J H Kleibeuker
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

9.  A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico.

Authors:  J Torres; Y Leal-Herrera; G Perez-Perez; A Gomez; M Camorlinga-Ponce; R Cedillo-Rivera; R Tapia-Conyer; O Muñoz
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  Y Glupczynski; M Labbé; W Hansen; F Crokaert; E Yourassowsky
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948
View more
  31 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

4.  Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori.

Authors:  Adnan Khan; Amber Farooqui; Hamid Manzoor; Syed Shakeel Akhtar; Muhammad Saeed Quraishy; Shahana Urooj Kazmi
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

5.  Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE.

Authors:  Mubarak S Alfaresi; Abida A Elkoush
Journal:  Indian J Gastroenterol       Date:  2010-07-25

6.  Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.

Authors:  Jungi Choi; Joo Young Jang; Joon Sung Kim; Hwa Young Park; Yon Ho Choe; Kyung Mo Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

Review 7.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

8.  Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori.

Authors:  Norazah Ahmad; Wan-Rasinah Zakaria; Sheikh-Anwar Abdullah; Ramelah Mohamed
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

9.  Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies.

Authors:  Nahla A Melake; Ghada H Shaker; Magdy A Salama
Journal:  Saudi Pharm J       Date:  2012-03-03       Impact factor: 4.330

10.  Clarithromycin resistance among Helicobacter pylori strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis.

Authors:  Teresa Alarcón; Alba E Vega; Diego Domingo; Maria Josefa Martínez; Manuel López-Brea
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.